Larger multicenter randomized trials are warranted to directly compare flumatinib with other second-generation TKIs (e.g., dasatinib, nilotinib) and to optimize treatment strategies for high-risk subgroups, including those with CML-LBP, IKZF1 deletion, or TP53 mutation. The gene discussed is IKZF1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.